Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 170Prostatic Neoplasms, Castration-Resistant 11Neoplasm Metastasis 11Metastatic Castration-resistant Prostate Cancer 7Metastatic Castration Resistant Prostate Cancer 6Prostate Cancer Metastatic 4Neoplasms 4Metastatic Castration-Resistant Prostate Cancer 4Urogenital Neoplasms 3Genital Neoplasms, Male 3Prostatic Diseases 2Neoplasms by Site 2Metastatic Castration-resistant Prostate Cancer (mCRPC) 2Genital Diseases, Male 2Castration-resistant Prostate Cancer 2Adenocarcinoma 2Urinary Bladder Neoplasms 1Stage II Prostate Adenocarcinoma 1Sleep Initiation and Maintenance Disorders 1Prostate Adenocarcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Oligometastatic Prostate Carcinoma 1Newly Diagnosed Oligometastatic Prostate Cancer 1Neoadjuvant Therapy 1NSCLC Harboring NRG1 Fusion 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Hormone Refractory Prostate Cancer 1Metastatic Castration-sensitive Prostate Cancer 1Metastatic Castration-resistent Prostate Cancer 1Metastatic Castration-resistant Prostate Neoplasms 1

Interventions

Prednisone 1Dexamethasone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hyperaldosteronism × Abiraterone Acetate × Genitourinary × Clear all
NCT01867710 2019-07-05

Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy

Janssen Pharmaceutica N.V., Belgium

Phase 2 Completed
164 enrolled 22 charts
Genitourinary

Hyperaldosteronism, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡